



# Biotech Daily

Thursday March 12, 2009

*Daily news on ASX-listed biotechnology companies*

## BIOPHARMICA

Biopharmica is looking for a partner to co-develop a new class of cancer anti-mitotic drugs for potential use against cancer.

Biopharmica said that with researchers from Western Australian Institute for Medical Research it had screened synthetic molecules and natural extracts for new anti-cancer drugs.

Biopharmica said the new anti-cancer drugs potentially inhibit cell proliferation, resulting in pronounced killing of all human cancer cell lines tested to date.

The company said the inhibition of cell proliferation and induction of cancer cell death was due to the anti-mitotic activity of these potential new drugs.

Anti-mitotic drugs, such as the blockbuster anti-cancer drug Taxol, are considered to be among the most clinically important cancer drugs discovered to date, generating revenue well in excess of \$US1 billion a year, the company said.

Biopharmica said that recent results with the anti-mitotic lead compound indicated "that development of this drug has the potential to similarly make a similar pronounced impact on cancer treatments and outcomes".

Biopharmica has contracted TM Ventures subsidiary the Australian Research network to represent its business development in Australia, Europe and the US.

Biopharmica said "an exceptional opportunity exists for a drug development company to participate in this lead compound development program".

Biopharmica was up 1.1 cents or 57.9 percent to three cents.